• Aliases: KRX-0401, D-21266
    • Inhibits AKT and MAPK pathways and modulates the balance between the MAPK and proapoptotic SAPK/JNK pathways, thereby inducing apoptosis
    • Currently under investigation in phase 3 clinical trial with MM and in phase 2 trials with advanced renal cell carcinoma, prostate cancer, and NSCLC
    • Recommended phase 2 dose: 200 mg orally daily
    • Half-life: 4 to 5 days
    • Metabolism: Potential substrate for CYP450, subfamilies unknown
    • Common side effects: Nausea/vomiting, diarrhea, musculoskeletal pain, fatigue, anorexia
    (Crul et al., 2002)
    Other topics in Targeted and Immunotherapy Agents